Press Releases

Northwell Health Implants Nation’s First Patient with SetPoint System for Treatment of Rheumatoid Arthritis

SetPoint Medical Raises $140 Million in Private Financing and Expands Leadership Team to Support Commercialization of Rheumatoid Arthritis Therapy

SetPoint Medical Receives FDA Approval for Novel Neuroimmune Modulation Therapy for Rheumatoid Arthritis

SetPoint Medical Receives Clinical Research Award at EULAR 2025 Congress

SetPoint Medical Appoints Tyler Binney to Its Board of Directors

SetPoint Medical Announces Filing of PMA to the FDA for Novel Neuroimmune Modulation Device for the Treatment of Rheumatoid Arthritis

SetPoint Medical Announces Late-Breaking Data from RESET-RA Study at ACR Convergence 2024

SetPoint Medical Receives FDA’s IDE Approval for U.S. Pilot Study of Neuroimmune Modulation Platform in Adults with Relapsing-Remitting Multiple Sclerosis

SetPoint Medical Announces Positive Topline Results from Landmark RESET-RA Study Evaluating Neuroimmune Modulation for the Treatment of Rheumatoid Arthritis

SetPoint Medical Accepted into FDA Total Product Life Cycle Advisory Program for Development of its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis

SetPoint Medical Receives FDA Breakthrough Device Designation for its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosis

SetPoint Medical Announces Publication of Data for Neuroimmune Modulation to Treat Crohn’s Disease in Journal of Crohn’s and Colitis

SetPoint Medical Appoints Rohan Seth as Chief Financial Officer

SetPoint Medical Announces $80M Preferred Stock Financing to Advance Company’s Novel Treatment for Autoimmune Diseases

SetPoint Medical Announces Expanded $65M Credit Facility to Support Development of the Company’s Novel Platform for Rheumatoid Arthritis

First Patient Enrolled in Stage 2 of Pivotal Study of SetPoint Medical’s Pioneering Technology for the Treatment of Rheumatoid Arthritis

SetPoint Medical Announces FDA Approval for Continuation of the RESET-RA Pivotal Study

SetPoint Medical Appoints Amy Derosier as Vice President of Clinical Affairs

Runway Growth Capital Announces a Senior Secured Term Loan of $35 Million to SetPoint Medical

SetPoint Medical CEO Murthy Simhambhatla Named to AIMBE College of Fellows

SetPoint Medical Announces First Patient Enrolled in the RESET-RA Study

SetPoint Medical Raises $64M in Preferred Stock Financing to Support Pivotal Trial for its Novel Bioelectronic Platform

SetPoint Medical Receives FDA Breakthrough Device Designation for its Novel Bioelectronic Platform

The Lancet Rheumatology Publishes Clinical Trial Data Demonstrating Promising Safety and Efficacy Profile for a Novel Bioelectronic Device in Patients with Drug Refractory Rheumatoid Arthritis

SetPoint Medical Receives IDE Approval for U.S. Pivotal Trial to Study its Bioelectronic Platform in Rheumatoid Arthritis Patients

SetPoint Medical to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum 2019

SetPoint Medical Announces Oral Presentation of Results from U.S. Pilot Study in Rheumatoid Arthritis Patients at American College of Rheumatology (ACR) Annual Meeting 2019

SetPoint Medical Reports Positive Results from its U.S. Pilot Study in Rheumatoid Arthritis

SetPoint Medical to Present Results From The U.S. Pilot Study in Rheumatoid Arthritis Patients at European Congress of Rheumatology (EULAR) 2019

SetPoint Medical to Present at Guggenheim 2019 MedTech Disruptors Summit

SetPoint Medical Reports New Data Demonstrating its Bioelectronic Medicine Effectively Reduces Crohn’s Disease Activity

SetPoint Medical to Present at Bank of America Merrill Lynch Health Care Conference 2019

SetPoint Medical Announces Data Supporting Continued Clinical Development of its Bioelectronic Device for Treatment of Rheumatoid Arthritis (RA)

SetPoint Medical Completes Enrollment in U.S. Pilot Study Evaluating Bioelectronic Device for Treatment of Rheumatoid Arthritis

SetPoint Medical Appoints Murthy Simhambhatla as President and Chief Executive Officer

SetPoint Medical Reports Positive Long-term Results from its Clinical Study of Bioelectronic Medicine to Treat Rheumatoid Arthritis

SetPoint Medical Presents Positive Data from its Clinical Study of Bioelectronic Medicine for Treatment of Crohn’s Disease

SetPoint Medical Appoints Ankit Shah to Lead Commercialization and Marketing

SetPoint Medical Announces U.S. Pilot Trial to Evaluate First Bioelectronic Device to Treat Rheumatoid Arthritis

SetPoint Medical Employees Dedicate Their Day to Hope Gardens

SetPoint Medical Reports Positive Results from Two Bioelectronic Medicine Studies at North American Neuromodulation Society Meeting

FDA Approves Investigational Device Exemption for SetPoint Bioelectronic Therapy Clinical Study in Rheumatoid Arthritis

SetPoint Medical Presents Early Data Showing Bioelectronic Medicine Accelerates Remyelination in Animal Model of Multiple Sclerosis

SetPoint Secures $30 Million Series D Equity Financing

SetPoint Medical Appoints David Chernoff, MD as Chief Medical Officer

Global Venture Firm NEA Joins SetPoint Medical Syndicate of Investors

SetPoint Medical Presents Positive Results In Ongoing Crohn’s Disease Study

SetPoint Medical Presents Positive Clinical Results in Crohn’s Disease

SetPoint Medical’s Progress Fuels Corporate Headquarters Relocation

SetPoint Medical Expands Management Team to Support Advancement of Bioelectronic Medicine Platform

Breakthrough First-in-Human Study Shows Vagus Nerve Stimulation Significantly Reduces Rheumatoid Arthritis Symptoms, Inhibits Cytokine Production

SetPoint Announces $15 Million Equity Financing, Adds Major Strategic Investor

SetPoint Announces First Trial of Bioelectronic Therapy to Treat Crohn’s Disease

SetPoint Medical Named One of the “Fierce 15” Leading Medical Technology Companies of 2013

SetPoint Medical Secures $27 Million Financing, Adding Action Potential Venture Capital/GSK, Boston Scientific and Covidien Ventures as New Investors